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ttp://dx.doi.org/10.1016/j.ajpath.2013.08.027Fibrosis pathophysiology is critically regulated by Smad 2e and Smad 3emediated transforming growth
factor-b (TGF-b) signaling. Disintegrin metalloproteases (Adam) can manipulate the signaling environment,
however, the role and regulation of ADAMs in renal ﬁbrosis remain unclear. TGF-b stimulation of renal cells
results in a signiﬁcant up-regulation of Adams 10, 17, 12, and 19. The selective Smad2/3 inhibitor SB
525334 reversed these TGF-beinduced changes. In vivo, using ureteral obstruction to model renal ﬁbrosis,
we observed increased Adams gene expression that was blocked by oral administration of SB 525334. Similar
increases in Adamgene expression also occurred in preclinicalmodels of hypertension-induced renal damage
and glomerulonephritis. miRNAs are a recently discovered second level of regulation of gene expression.
Analysis of 30 untranslated regions of Adam12 and Adam19 mRNAs showed multiple binding sites for miR-
29a, miR-29b, and miR-29c. We show that miR-29 family expression is decreased after unilateral ureter
obstruction and this signiﬁcant decrease inmiR-29 family expressionwas observed consistently in preclinical
models of renal dysfunction and correlated with an increase in Adam12 and Adam19 expression. Exogenous
overexpression of the miR-29 family blocked TGF-bemediated up-regulation of Adam12 and Adam19 gene
expression. This study shows that Adams are involved in renal ﬁbrosis and are regulated by canonical TGF-b
signaling and miR-29. Therefore, both Adams and the miR-29 family represent therapeutic targets for renal
ﬁbrosis. (Am J Pathol 2013, 183: 1885e1896; http://dx.doi.org/10.1016/j.ajpath.2013.08.027)Supported by the Medical Research Council UK, the British Heart
Foundation Chair of Translational Cardiovascular Sciences (A.H.B.), and
by a personal Kidney Research UK Fellowship (PDF6/2012 to L.D.).Fibrosis of the tubulointerstitium is the common end point
of most progressive renal diseases and consistently has been
shown to be the best histologic predictor of progression
toward end-stage renal failure.1 This point of no return in-
volves tubular atrophy, leukocyte inﬁltration, myoﬁbro-
blast differentiation, activation, and proliferation and the
excess accumulation of extracellular matrix, resulting ulti-
mately in scarring and loss of function.2 Transforming
growth factor-b (TGF-b) initiates ﬁbrosis pathogenesis
predominantly mediated by downstream effector mole-
cules, known as Smads.3e5 Binding of active TGF-b1,
synthesized by epithelial and mesangial cells in response to
injury and by activated macrophages, to TGF-b type 1 and
type 2 receptors results in the initiation of a signaling
cascade brought about by the phosphorylation, nuclear
translocation, and regulation of gene expression by Smads 2
and 3; a phenomenon termed canonical signaling.6 Shortstigative Pathology.
.endogenous 22-nucleotide noncoding RNAs capable of
posttranscriptional gene regulation7 also have been shown
to regulate renal ﬁbrosis.8,9 Recently, we and others
described the presence of a canonical TGF-beregulated
miRNA signature in renal disease.10,11 The miR-29 family,
consisting of miR-29a, miR-29b, and miR-29c, has been
shown to be a critical mediator of disease pathophysi-
ology.12 Emerging evidence suggests that the miR-29
family is regulated by canonical TGF-b signaling via
p-Smad 3.13 The miR-29 family is expressed differentially
in healthy renal tissue and ﬁbrosis. In the experimental
unilateral ureter obstruction (UUO) model of renal ﬁbrosis,
it previously was shown that expression of the miR-29
Ramdas et alfamily is reduced after injury.13 Furthermore, forced
expression of miR-29b before or 4 days after UUO was
protective from interstitial ﬁbrosis induced by UUO.13 The
miR-29 family is able to post-transcriptionally regulate a
cohort of ﬁbrosis-relevant genes, including collagens and
various metalloproteases.14,15
Metzincin metalloproteases, which includes the classic
matrix metalloproteases and their tissue inhibitors, have
been shown to play important roles in regulating matrix
turnover in normal nephrogenesis and in ﬁbrotic renal dis-
ease.16 Disintegrin metalloproteases (Adams) are members
of this class that can regulate key cellular and acellular
processes.17 Thus, they potentially can regulate both the
inﬂammatory and the ﬁbrotic aspects of renal pathophysi-
ology. Adams 10 and 17 classically have been studied in the
proinﬂammatory tumor necrosis factor turnover in tissue,18
which in turn determines the activation status of the
cellular components of renal inﬂammation.19,20 Adams 10
and 12 have been shown to facilitate leukocyte inﬁltra-
tion21,22 and cleave E-cadherin, thereby promoting inva-
siveness in differentiated myoﬁbroblasts.23 Members of the
epidermal growth factor signaling pathway, crucial in
myoﬁbroblast differentiation and resulting basement mem-
brane invasion, have been shown to be cleaved selectively
by Adams 10, 17, and 19.24,25 Adams are the central and
rate-limiting factors in the cross-talk between epidermal
growth factor and the angiotensin II pathways, a phenom-
enon now termed triple membrane pass signaling.26 Similar
to other metzincin proteases, Adams can regulate extracel-
lular matrix turnover in tissue.27e29
The role of Adams in ﬁbrosis, including renal ﬁbrosis,
remains largely unknown. There is considerable evidence
to associate Adams with renal disease. Melenhorst et al30e32
and Mulder et al33showed increased expression of Adam17
and Adam19 mRNA in renal transplant and nonetrans-
plant-related ﬁbrotic disease in humans. Lautrette et al34
showed that inhibition of Adam17 with the pharmacologic
inhibitor WTACE2 reduced angiotensin IIeinduced renal
ﬁbrotic lesions in mice and Schramme et al35 showed that
Adam10-mediated shedding of CXCL16 from cul-
tured thick ascending limb distal tubular cells induced
CXCR6-expressing leukocyte and lymphocyte chemotaxis
in vitro. Although regulation of matrix metalloproteases and
tissue inhibitors of matrix metalloproteases at both the gene
and functional levels by TGF-b has been well doc-
umented,36e38 we hypothesized that the regulation Adams
also are mediated by TGF-b.
Therefore, we determined ADAMs expression in rele-
vant in vitro and in vivo experimental models of renal
ﬁbrosis. Because TGF-b is involved in ﬁbrosis patho-
physiology, we then determined if canonical TGF-b
signaling regulates Adams using a speciﬁc small molecule
inhibitor. Furthermore, because the miR-29 family targets
included Adam12 and Adam19, we examined whether
these Adams potentially can be regulated by modulation
of miR-29.1886Materials and Methods
In Vitro Model of Renal Fibrosis
Rat tubular epithelial cells (NRK52E) were cultured ac-
cording to ATCC (Manassas, VA) protocols. They were
seeded, grown to subconﬂuent densities, and were subjected
to a 48-hour serum starvation (0.2% fetal bovine serum vol/
vol in media) to synchronize the cell cycle. Cells were
stimulated with 10 ng/mL (wt/vol) recombinant TGF-b
(R&D Systems, Abingdon, UK) over a 4-day time course,
with TGF-b being replenished every 48 hours. 6-[2-Tert-
butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxa-
line (SB 525334; R&D Systems) is an orally bioavailable
and selective small-molecule inhibitor that blocks ALK5
serine/threonine kinase activity and prevents phosphoryla-
tion of the R-Smads 2 and 3 and their subsequent nuclear
translocalization and gene activation.39 SB 525334 used at 1
mmol/L wt/vol in vehicle (0.1% dimethyl sulfoxide in PBS)
was added to cells 60 minutes before TGF-b stimulation and
replenished every 24 hours.
Animal Models
All protocols and surgical procedures were approved by the
local animal care committee. Animal experiments were in
accordance with the Animals Scientiﬁc Procedures Act UK
of 1986.
Unilateral Ureter Obstruction
Eight-week-old male C57/BL6 mice weighing approxi-
mately 21 to 23 g were used. Animals were anesthetized by
isoﬂurane inhalation and underwent a midline laparotomy;
the right ureter was exposed by blunt dissection. Complete
ureteral obstruction was performed by tying two 4-0 silk
sutures around the isolated ureter. The midline incision then
was resutured. Control groups consisted of sham surgeries
including laparotomy and ureter handling but not ligation.
Animals were sacriﬁced 3, 7, and 14 days after surgery and
kidneys were removed for analysis. To assess the effect of
TGF-b in vivo, SB 525334 in 0.1% vol/vol dimethyl sulf-
oxide in PBS was administered daily at 10 mg/kg/d body
weight by standard oral gavage in a ﬁnal volume of 100 mL.
Animals were sacriﬁced on day 7 and kidneys were snap
frozen and stored at 80C before analysis.
Genetic Rat Model of Hypertension-Induced Renal
Damage
Inbred colonies of stroke-prone, spontaneously hypertensive
and Wistar-Kyoto rats have been developed and maintained
at the University of Glasgow since 1991, as described pre-
viously.40 All animals were sacriﬁced at 21 weeks. After
sacriﬁce, kidneys were removed, snap frozen, and stored
at 80C before analysis.ajp.amjpathol.org - The American Journal of Pathology
Figure 1 Effect of TGF-b on Adam expression in tubular epithelial cells.
Rat tubular epithelial NRK52E cells were stimulated with 10 ng/mL TGF-b
over a 4-day time course. Gene expression was measured by qPCR using
speciﬁc TaqMan probes (Life Technologies) for Adam10, Adam17, Adam12,
and Adam19 and normalized to glyceraldehyde-3-phosphate dehydroge-
nase (Gapdh). RQ  RQmax. *P < 0.05, **P < 0.01 versus unstimulated
time-matched controls. Results are representative of three independent
experiments. RQ, relative quantiﬁcation.
ADAM Regulation in Renal FibrosisInduction of Glomerulonephritis
Male Wistar-Kyoto rats (Harlan, Wyton, UK) (age, 7 to 12
weeks) were used throughout the study. All protocols and
surgical procedures were approved by the local animal care
committee. Animals were age-matched at sacriﬁce to mini-
mize age-related differences in miRNA expression and gene
expression. For the induction of glomerulonephritis, rats
were infused intravenously with 2 mg/kg anti-Thy1 antibody
(ER4) three times, 1 week apart. After sacriﬁce at 7 days,
kidneys were removed and portions were ﬁxed in 10%
formalin or snap frozen and stored at80C before analysis.
RNA Extraction and Gene Expression Analysis
RNA was extracted lysis using the miRNeasy kit (Qiagen,
Manchester, UK) following the manufacturer’s instructions,
and quantiﬁed using a NanoDrop ND-1000 Spectrophotom-
eter (ThermoFisher Scientiﬁc, Waltham, MA). For cDNA
synthesis, 1 mg of total RNA (cell or whole tissue) was reverse-
transcribed using the manufacturer’s instructions (Life Tech-
nologies, Paisley, UK) and quantitative real-time PCR (qPCR)
was performed using speciﬁc inventoried gene expression or
stem-loop miRNA primer/probes (Life Technologies) on the
Applied Biosystems 7900 HT real-time PCR system. Mouse
glyceraldehyde-3-phosphate dehydrogenase or U87 (rat)/U6
(mouse) primer/probes were used as endogenous controls for
gene and miRNA expression, respectively.
Immunocytochemistry
Immunocytochemistrywas performed on cells grown on sterile
18-mm coverslips (Menzel-Glazer, Braunschweig, Germany)
and ﬁxed with 4% (wt/vol) paraformaldehyde and per-
meabilized by using 0.1% (vol/vol) Triton X-100 (Sigma-
Aldrich,Gillingham,UK).These cellswere probedusing rabbit
polyclonal anti-Adam (all 1:100;Abcam, Cambridge, UK) and
p-Smad2/3 speciﬁc (1:100; Santa Cruz, Santa Cruz, CA) anti-
bodies followed by Alexa-Flour 488 tagged secondary anti-
body (Invitrogen, Paisley, UK). Coverslips were mounted onto
slides using DAPI Prolong-Gold (Molecular Probes, Paisley,
UK)mountant and analyzedbyﬂuorescencemicroscopywith a
Zeiss LSM510 (Carl-Zeiss AG, Oberkochen, Germany).
Tissue sections (3 mm) were deparafﬁnized, hydrated, and
endogenous peroxidases were quenched using 0.3% H2O2 in
methanol. Heat-mediated antigen retrieval was performed
using citrate buffer (pH 6.6). Sections were serum- and
avidin/biotin-blocked (Vector Laboratories, Peterborough,
UK) and probed using 1:100 dilution of rabbit polyclonal
primary antibody (Abcam) overnight at 4C. They then were
washed and probed with 1:400 dilution of biotinylated anti-
rabbit secondary antibody (Vector Laboratories) and horse-
radish-peroxidaseeconjugated streptavidin, and detected
using diaminobenzidine substrate (Vector Laboratories). The
sections were visualized and imaged using a Zeiss Axiovert
microscope (Carl-Zeiss AG).The American Journal of Pathology - ajp.amjpathol.orgImmunoﬂuorescence
Sections of mouse kidneys (3 mm)were prepared as described
earlier and heat-mediated antigen retrieval was performed
using citrate buffer (pH 6.6). Sections were blocked in buffer
containing 15% (vol/vol) goat serum and 0.05% (vol/vol)
Tween 20 in Tris-buffered saline and probed using p-smad 2/
3 (1:100) overnight at 4C, washed, and probed with a 1:400
dilution of biotinylated anti-rabbit secondary antibody
(Vector Laboratories). Slides were treated with 0.1% vol/vol
Sudan Black in methanol (Sigma) for 10 minutes at room
temperature in the dark to minimize background ﬂuores-
cence, followed by treatment with 100 mg/mL DAPI for 10
minutes. ProLong Gold with DAPI (Invitrogen) was placed
on clean plain glass coverslips and slides were placed onto
coverslips, tissue-side down, over the drop, and cured over-
night on the bench top. The sections were imaged and imaged
using a Zeiss LSM510 confocal microscope. Green ﬂuores-
cent nuclei were counted in six nonoverlapping images per
kidney section per animal and are represented as a percentage
ratio to the number of DAPI-stained total nuclei. At least 100
nuclei were counted per image.
Adam10/17 Activity Assay
An Adam17 activity assay was performed based on cleav-
age of ﬂuorescent substrate. Brieﬂy, an enzyme versus
substrate reaction was set up at a ﬁnal volume of 100 mL,
using half the dilution range from 1.6 to 0.2 ng/mL of re-
combinant murine Adam17 peptide (R&D Systems) or 20
mg whole-tissue protein lysate. The reaction was initiated
with the addition of 10 mmol/L Adam10/17-speciﬁc sub-
strate Mca-P-L-A-Q-A-V-Dpa-R-S-S-S-R-NH2 Fluorogenic
Peptide Substrate III (R&D Systems) and performed at
37C. Fluorescence intensity was determined with the1887
Ramdas et alﬂuorescence plate reader SpectraMax 2.0 Station (Molecular
Devices) using an excitation wavelength at 320 nm and
emission at 405 nm every 5 minutes for 20 minutes. Fluo-
rescence kinetics curves were constructed by plotting ﬂuo-
rescence intensity versus enzyme concentration. A further
Vmax versus enzyme concentration curve was constructed
from log-phase values from the kinetics curve. The
Adam10/17 concentration in tissue lysates was extrapolated
from the Vmax standard curve.1888Manipulation of miR-29 Levels
NRK52E cells were plated in 6-well plates at 8  104
cells per well. Cells were transfected with mirVana miR-
29a, miR-29b, or miR-29c mimics (Ambion, Paisley, UK)
individually or in combination at a ﬁnal concentration of
50 nmol/L complexed with Lipofectamine (Invitrogen).
The Lipofectamine:miRNA complex was left on cells for
5 hours with intermittent shaking, then supplemented withFigure 2 Adamexpression in kidneys after UUO.
RNA was extracted from whole kidneys after UUO
surgery. A: Gene expression was measured by qPCR
using speciﬁc TaqMan probes for Adam10, Adam17,
Adam12, and Adam19 and normalized to glyceral-
dehyde-3-phosphate dehydrogenase (Gapdh). RQ
RQmax. B: Adam10/17 enzyme activity assay on
whole-kidney protein. Fluorescent substrate gen-
eration versus time curves. Active enzyme concen-
trations in whole lysates (ng of enzyme/mg whole
protein). Means  SEM. **P < 0.01, ***P < 0.001
versus sham kidneys. C: Adam12 and Adam19 (D)
expression in renal cortex analyzed by immunohis-
tochemistry using speciﬁc antibodies. Inset: Iso-
type (ISO) stained sections. Arrowheads denote
proximal tubules, and arrows denote dilating tu-
bules. Scale bars: 100 mm. N Z 6 mice per group.
RQ, relative quantiﬁcation.
ajp.amjpathol.org - The American Journal of Pathology
ADAM Regulation in Renal Fibrosis10% serum containing media. Twelve hours later the cells
were washed with PBS and cells were replenished with
fresh serum-free media. After 48 hours of serum starving,
cells were stimulated with 10 ng/mL TGF-b and left for
72 hours. Total RNA was extracted and miRNA and gene
levels were quantiﬁed.Figure 3 SB 525334 abrogates TGF-beinduced Adam expression
in vitro. A: Gene expression measured by qPCR using speciﬁc TaqMan
probes for Adam10, Adam17, Adam12, and Adam19 and normalized to
glyceraldehyde-3-phosphate dehydrogenase (Gapdh). RQ  RQmax.
**P < 0.01, versus unstimulated time-matched controls. yP < 0.05
versus þTGF-b. B: Immunoﬂuorescent analysis on rat tubular epithelial
NRK52E cells after 72 hours TGF-b  SB 525334 using Adam-speciﬁc
antibodies. Scale bars: 20 mm. Results are representative of three inde-
pendent experiments. RQ, relative quantiﬁcation; Un, unstimulated time
matched control cells.
The American Journal of Pathology - ajp.amjpathol.orgStatistical Analysis
All in vitro work was performed in triplicate and repeated
on at least three independent occasions. In vivo experiments
were conducted in groups of six animals. Analysis of sig-
niﬁcance across two groups was performed by a standard
unpaired 2-tailed Student’s t-test and analysis across mul-
tiple groups was performed by one-way analysis of variance
followed by the Tukey post hoc correction. Signiﬁcance was
set at a P value less than 0.05.Results
TGF-b Stimulation Induces Adams Expression in
Cultured Renal Cells
We and others previously have shown that NRK52E in
response to 10 ng/mL of TGF-b treatment acquire a proﬁ-
brotic, secretory, and invasive mesenchymal-like pheno-
type.10,41 We determined changes in Adams gene expression
in response to TGF-b stimulation in NRK52E over a 4-day
time course. TGF-b stimulation induced Adams gene
expression in a time-dependent manner. Signiﬁcant increases
were seen in Adam10, Adam17, Adam12, and Adam19 by
72 hours compared with time-matched untreated controls
(Figure 1). Similar time-dependent TGF-beinduced up-
regulation of Adams gene expression also was seen in
mesangial cells in culture (Supplemental Figure S1). Adam 9,
15, and 33, the other remaining members of the proteolytic
group of Adams with renal expression, however, remained
unresponsive to TGF-b treatment of renal cells and therefore
were omitted from further analysis (Supplemental Figure S2).Increased ADAMs Expression Is Observed in Obstructed
Mouse Kidneys
To investigate whether Adams expression was altered
in vivo, we used the well-established UUO model in which
TGF-b is known to be the primary proﬁbrotic mediator42,43
and quantiﬁed gene expression of Adam at days 3, 7, and 14
from whole-tissue lysates of obstructed kidneys. A similar
time-dependent increase was observed in vivo, with all
Adams studied showing signiﬁcantly increased expression
proﬁles compared with time-matched sham kidneys at all
time points after obstruction (Figure 2A). Renal protein
lysates from obstructed kidneys contained signiﬁcantly
higher twofold active Adams 10 and 17 levels on day 3 after
injury (Figure 2B). Immunohistochemical analysis on renal
cortices for Adams 12 and 19 showed up-regulation in UUO
(Figure 2, C and D). Adam12 expression appeared to be
highest in the proximal tubules with only marginal
glomerular, distal tubular, or interstitial staining. Adam19
expression was greatest in dilating tubules by day 3, with
little glomerular mesangial and no interstitial staining.
However, by day 7 the expressions appeared pan-corticular.1889
Ramdas et alThese results suggest that a speciﬁc cohort of Adams (ie,
Adams 10, 12, 17, and 19) is up-regulated in an experi-
mental model of TGF-bedriven renal ﬁbrosis.
SB 525334 Abolishes TGF-beInduced Adam Expression
in Vitro and in Vivo
We next sought to determine whether TGF-beinduced
ADAMs expression was mediated by Smad 2/3. We used a
selective Smad phosphorylation inhibitor SB 525334
concomitantly with TGF-b stimulation. SB 525334 treatment
blocked TGF-beinduced proﬁbrotic phenotypic changes,
including up-regulation of collagen, a-smooth muscle actin,1890and loss of E-cadherin, and diminished p-Smad 2/3 nuclear
staining compared with vehicle-treated cells stimulated with
TGF-b alone (Supplemental Figure S3).
Abrogation of canonical TGF-b signaling by SB 525334
substantially affected growth factoreinduced Adams gene
expression in vitro (Figure 3A). Similar changes in ADAMs
were observed at the protein expression level as analyzed by
immunoﬂuorescent imaging using speciﬁc ADAMs anti-
bodies in which the readily detectable up-regulation result-
ing from TGF-b stimulation was abrogated by SB 525334
treatment (Figure 3B).
SB 525334 previously was shown to be orally bioavail-
able and daily administration at 10 mg/kg body weightFigure 4 SB 525334 decreases ADAM expres-
sion in UUO. A: Gene expression measured on
whole-kidney RNA by qPCR using speciﬁc TaqMan
probes for Adam10, Adam17, Adam12, and
Adam19 and normalized to glyceraldehyde-3-
phosphate dehydrogenase (Gapdh). RQ  RQmax.
B: Adam10/17 enzyme activity assay on whole-
kidney protein. Fluorescent substrate generation
versus time curves. Active enzyme concentrations
in whole lysates (ng of enzyme/mg whole protein).
Means  SEM. **P < 0.01, ***P < 0.001 versus
vehicle sham kidneys. yP < 0.05 versus vehicle
UUO. ADAM12 (C) and ADAM19 (D) expression in
renal cortex analyzed by immunohistochemistry
using speciﬁc antibodies. Inset: Isotype (ISO)
stained sections. Arrowheads denote proximal
tubules, and arrows denote dilating tubules. Scale
bars: 100 mm. N Z 6 mice per group. RQ, relative
quantiﬁcation.
ajp.amjpathol.org - The American Journal of Pathology
ADAM Regulation in Renal Fibrosisameliorated collagen I a, III a, and plasminogen activator
inhibitor-1 expression, and decreased proteinuria in a model
of puromycin aminonucleoside nephritis.44 We therefore
used SB 525334 in vivo and examined kidneys at day 7 after
obstruction to reﬂect the transition phase from acute to
chronic injury.
Inhibition of canonical TGF-b signaling decreased
Adam10, Adam17, and Adam19 gene expression by 50%,
60%, and 70%, respectively, compared with control animals
undergoing UUO (Figure 4A). The increase in Adam12 gene
expression in UUO was completely abolished in the group
administered SB-525334. Enzyme activity assays showed
that UUO animals administered SB-525334 expressed lower
levels of active ADAMs 10 and 17 in kidneys compared with
the vehicle UUO group, although values remained signiﬁ-
cantly greater than those in sham controls (Figure 4B).
Proximal tubular ADAM12 expression observed in control
UUO kidneys largely was absent in the cortices of obstructedFigure 5 miR-29 expression in rat tubular epithelial NRK52E cells. A: Predict
(UTRs), based on TargetScan Release 5.1 (http://www.targetscan.org, last accesse
exact matches to residues 2 to 8 of the mature miR-29a, miR-29b, and miR-29c. mi
29a, miR-29b, and miR-29c, and normalized to U87 after TGF-b stimulation at the
treatment at 72 hours (C). RQ  RQmax. *P < 0.05, **P < 0.01, and ***P < 0.00
Results are representative of three independent experiments. RQ, relative quanti
The American Journal of Pathology - ajp.amjpathol.orgkidneys of animals receiving SB-525334 (Figure 4C). A
similar loss of ADAM19 was observed but some dilating
tubules still showed ADAM19 expression (Figure 4D).
Taken together, these results show that increased
expression of ADAMs 10, 17, 12, and 19 in renal ﬁbrosis is
mediated by canonical Smad 2/3 signaling.
miR-29 Can Regulate Adam12 and Adam19 Expression
Members of the miR-29 family are emerging as key regula-
tory switches in gene expression in ﬁbrotic injury and
development through their ability to negatively regulate gene
expression by binding to 30-untranslated regions of target
mRNAs that include various metzincin metalloproteases and
prevent expression.45,46 The 30- untranslated regions of both
Adam12 and Adam19 mRNA contain multiple conserved
putative 7 and 8mer miR-29 binding sites (Figure 5A) that are
conserved across species. We therefore assessed whethered miR-29 target sites in the Adam12 and Adam19 30-untranslated regions
d October 15, 2013). Nucleotides are highlighted in the 30-UTRs that show
RNA expression was measured by qPCR using speciﬁc TaqMan probes for miR-
indicated time points (B), and TGF-b stimulation and SB-525334 inhibitor
1 versus unstimulated time-matched controls. yP < 0.05 versus CTLþ TGF-b.
ﬁcation; Un, unstimulated time matched controls.
1891
Figure 6 Adam expression in kidneys after UUO. RNA was extracted from
whole kidney after UUO surgery. miRNA expression was measured by quan-
titative RT-PCR using a speciﬁc TaqMan probes for miR-29a, miR-29b, and
miR-29c, and normalized to U87 after RQ  RQmax. *P < 0.05. nZ 6 per
group. RQ, relative quantiﬁcation. White bars indicate sham operated ani-
mals; black bars, animals who have undergone UUO surgery.
Figure 7 The miR-29 family and Adam expression correlate in preclinical
models of renal damage. A and B: RNA was extracted from whole kidneys
from animals at 21 weeks of age (nZ 3 to 4 per group). A: The miR-29 family
expression was measured by qPCR using speciﬁc TaqMan probes for miR-29a,
miR-29b, and miR-29c, and normalized to U87. B: Gene expression was
measured by qPCR using speciﬁc primers and normalized to glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). *P< 0.05, **P< 0.01 versus Wistar-
Kyoto (WKY). C and D: RNA was extracted from whole kidneys from animals
with induced glomerulonephritis and the animals were sacriﬁced at 7 days. C:
The miR-29 family expression was measured by qPCR using speciﬁc TaqMan
probes for miR-29a, miR-29b, and miR-29c, and normalized to U87. D: Gene
expression was measured by qPCR using speciﬁc primers and normalized to
Gapdh. *P < 0.05 versus control. RQ, relative quantiﬁcation.
Ramdas et alAdam expression in this model can be regulated by miR-29
modulation. Consistent with previously published re-
ports,13,15,47 TGF-b stimulation of NRK52E resulted in
progressive loss of all three members of the miR-29 family
(Figure 5B) and this loss was rescued by SB-525334 treat-
ment of TGF-bestimulated cells (Figure 5C).
In vivo, we initially checked that miR-29 expression after
UUOwas decreased as previously reported.13 Using the same
RNA extracted from the tissue we observed the increase in
Adam10, Adam12, Adam17, and Adam19, after UUO we
examined the expression of miR-29a, miR-29b, and miR-
29c. We found signiﬁcant decreases in the miR-29 family 7
days after UUO surgery (P < 0.05), which remained signiﬁ-
cantly reduced at 14 days (Figure 6). To examine whether the
link between miR-29 family loss and an increase in Adam12
and Adam19 was more broadly relevant in models of renal
pathology we used two additional preclinical models that
resulted in renal damage induced by divergent pathologic
stimuli; the stroke-prone, spontaneously hypertensive rat10,40
and the anti-Thy1.1 model of glomerulonephritis.10,48 We
observed that the miR-29 family was reduced signiﬁcantly in1892both models (Figure 7, A and C). Examining ADAM
expressionweobserved thatAdam10,Adam12,Adam17, and
Adam19 were increased in the stroke-prone, spontaneously
hypertensive compared with the normotensive reference
strain (Figure 7B), whereas in the anti-Thy1.1 model (a mild
renal damage was observed) there were signiﬁcant changes in
Adam12 and Adam19 only (Figure 7D).
We next sought to determine whether exogenous over-
expression of the three individual members of the miR-29
family or an equimolar mix of miR-29a, miR-29b, and miR-
29c could modulate Adam12 and Adam19 expression in
response to TGF-b treatment. To achieve this, miR-mimics
containing mature sequences of the miR-29 family members
were transfected into NRK52E cells. Successful over-
expression of these miRNA was conﬁrmed by qPCR at 48
hours after transfection (Figure 8A).
Induction of differentiation from the epithelial to ﬁbroblast
phenotype in NRK52E by TGF-b resulted in increased Col1a
and Col3a expression, and this effect was rescued by over-
expression of the miR-29 family (Figure 8B). However, the
increase in a-smooth muscle actin and tissue inhibitor of
matrix metalloprotease 1 expression was not altered under
these conditions (Figure 8C). This concurs with published
data that showed that Col1a and 3a are direct targets of the
miR29 family,15,49 whereas a-smoothmuscle actin and tissue
inhibitor of matrix metalloprotease 1 are not direct targets.
We then subjected miR-29 mimic transfected cells to 72
hours of TGF-b stimulation and determined the effect on
Adams gene expression. Expression of Adam12 andajp.amjpathol.org - The American Journal of Pathology
Figure 8 miR-29 overexpression in rat tubular
epithelial NRK52E cells. A: Exogenous over-
expression of the miR-29 family measured by qPCR
using speciﬁc TaqMan probes for miR-29a, miR-
29b, and miR-29c, and normalized to U87. Gene
expression of miR-29 targets (B) and nontargets
(C) measured by qPCR in NRK52E overexpressing
miR-29. RQ  RQmax. *P < 0.05, ***P < 0.001
versus unstimulated controls. yyP < 0.01 versus
stimulated CTL miR-mimic. zzP < 0.01 versus
unstimulated CTL miR-mimic. a-SMA, a-smooth
muscle actin; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; TIMP, tissue inhibitor of matrix
metalloprotease. RQ, relative quantiﬁcation.
ADAM Regulation in Renal FibrosisAdam19 were both down-regulated after miR-29 over-
expression (Figure 9, A and B). Overexpression of miR-29b
or equimolar doses of miR29-a, miR-29b, and miR-29c
together signiﬁcantly blocked TGF-beinduced Adam12
expression, whereas miR-29a or miR-29c had no effect on
gene expression (Figure 9A). Adam19 expression was
decreased signiﬁcantly with overexpression of miR-29b or
miR-29c and in cells receiving equimolar miR-29a,
miR-29b, and miR-29c (Figure 9B).
Collectively, this suggests that the beneﬁcial effect observed
with manipulation of the miR-29 family likely is mediated in
part through the regulation of collagen overexpression and
Adams 12 and 19, which are induced by TGF-b.Discussion
In this article we report that Adams 10, 12, 17, and 19 are
up-regulated in TGF-bedriven renal ﬁbrosis in vitro and
in vivo and that canonical Smad 2/3 signaling regulates
Adams gene expression. We show that the loss of the miR-
29 family is a signiﬁcant feature in renal damage, occurs
regardless of the injury, and this loss correlates with an
increase in the expression of ADAM family members. In
addition, we show that Adam12 and Adam19 are regulated
by miR-29 manipulation in vitro.
Adam10 and Adam17 are perhaps the most widely studied
members of the ADAMs family.50,51 Recently, Lu et al52
showed that TGF-b stimulation up-regulated Adam17
expression and increased the invasiveness of T98G glioma
cells, whereas preconditioning with a pan ALK inhibitorThe American Journal of Pathology - ajp.amjpathol.orgSB431542 reversed these changes. This is in accordance with
changes we have observed in renal tubular epithelial and
mesangial cells by administering the speciﬁc ALK5 inhibitor
SB-525334. Treatment with SB-525334 resulted in a 50% to
60% reduction in Adam10 and Adam17 gene expression,
respectively. Similar time-dependent up-regulation and inhi-
bition in response to SB-525334 administration also was
observed in vivo. Promoter analysis of Adam10 and Adam17
showed that these Adams are devoid of cis-regulatory
elements such as the TATA or CAAT sequences in their
promoters; a category of genes that also includes the classic
TGF-beregulated matrix metalloprotease 2 and matrix met-
alloprotease 14.53 Work by Prinzen et al54 in characterizing
the Adam10 promoter showed the presence of multiple CpG
islands with potential TGF-berelated transcription factors
Sp1 and Smad 3 binding sites in the region lying between
508 and the transcriptional start site. Similar sequences were
found between -290 bp and the transcriptional start site of the
Adam17 promoter.55 Taken together with data reported here,
this suggests that Adam10 and Adam17 are directly respon-
sive to TGF-b transcriptional regulation. Consistent with
previously published reports, immunoﬂuorescent staining
showed perinuclear localization of Adams in unstimulated
NRK52E.56
Adam12 and Adam19 belong to the meltrin subfamily of
ADAM and share signiﬁcant sequence homology and partial
substrate speciﬁcity.57 There is evidence to suggest that
TGF-bemediated up-regulation of Adam is owing to inhibi-
tion of repressors such as ski-related novel protein N in a
Smad2/3-dependent manner.58 In this study, Adam did not
show early responses to TGF-b stimulation but increased1893
Figure 9 miR-29 regulates Adam12 and Adam19 in vitro. Gene expres-
sion of Adam12 (A) and Adam19 (B) after miR-29 family overexpression.
*P < 0.05, **P < 0.01 versus unstimulated controls. yyP < 0.01 versus
stimulated CTL miR-mimic. zP < 0.05, zzP < 0.01 versus unstimulated CTL
miR-mimic. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. CTL, con-
trol time matched cells; RQ, relative quantiﬁcation.
Figure 10 Mechanism of ADAM expression in ﬁbrosis and the Smad2/3-
miR-29-ADAM axis. TGF-b binding induces receptor kinaseemediated
phosphorylation of Smads 2 and 3. Phosphorylated Smads then translocate
to the nucleus and initiate Adam gene expression. p-Smad 2/3 negatively
regulates miR-29 expression, the presence of which represses Adam12 and
Adam19 expression post-transcriptionally. Treatment with SB-525334 in-
hibits Smad 2/3 phosphorylation and hence its downstream effects on gene
and miRNA expression. These mechanisms combine to result in decreased
Adam gene expression.
Ramdas et alrapidly after 48 hours, and SB 525334 treatment completely
blockedAdam12 expression.Adam12 also is regulated via NF-
kB p65 as a response to Notch1 activation in breast cancer
models.59,60 Although Adam17 is thought to act in the
counter-regulatory axis on TGF-b signaling,61 Adam12 has
been shown to enhance TGF-b signaling via stabilization of
the TGF-bR1 and TGF-bR2 dimer and to enhance receptor
Smad 2/3 phosphorylation.62 Taken together, this suggests that
TGF-b signaling inhibition potentially could affect a feed-
forward mechanism in Adam12 gene expression and that it
can be regulated by TGF-b at multiple levels.
Transcriptional regulation of Adam19 is not very well
understood. It previously was reported via microarray
analysis that TGF-b stimulation of A549 alveolar epithelial
cells led to a signiﬁcant increase in Adam19 gene expres-
sion as early as 4 hours after stimulation.63 Here, Adam19
expression was seen to change only after 48 hours of
stimulation. Chan et al64 reported that Adam19 expression
in ovarian cancer cells was regulated by histone deacylation
mediated by TGF-b1 via Smad 4. Early sequence analysis
studies showed potential upstream and downstream regula-
tory elements in murine Adam19 gene. The positive1894regulatory sequence upstream of the transcriptional start site
contained, similar to the case of Adam10 and Adam17,
multiple CpG islands with potential Sp1 binding sites.
miRNA offer an additional post-transcriptional checkpoint
in gene regulation. miRNA previously have been shown to
regulate Adam gene regulation in experimental models of
disease and development. Computational analysis and
Adam10 30-untranslated region luciferase assays showed sig-
niﬁcant inhibition via miR-1306, miR-103, and miR-107.65
miR-126 overexpression was able to inhibit Adam9-
mediated EMT-like processes in pancreatic cancer cells66
and Adam17 has been implicated as a target of miR-14567
and miR-222.67 miR-29 has conserved binding sites at the 30
untranslated regions of Adam12.68 Our study shows miR-29
regulation in canonical TGF-bedriven models of renal
ﬁbrosis, conﬁrming previous reports in similar models.69 In
addition, we provide evidence that miR-29 modulation regu-
lates Adam19 expression. Although triple transfections repress
Adam12 and Adam19 expression to baseline, the individual
isoforms miR-29b and miR-29c are sufﬁcient to signiﬁcantly
inhibit Adam12 and Adam19 expression, respectively. The
physiologic relevance of such isoform-speciﬁc inhibition
needs to be investigated further. It previously has been shown
that miR-29b localizes to the tubules.13 In our study, we show
that Adam12 and Adam19 expression also is localized within
the tubules (Figure 2). This similarity in localization may beajp.amjpathol.org - The American Journal of Pathology
ADAM Regulation in Renal Fibrosisimportant because we hypothesized that there is interplay
between miR-29 expression and regulation of Adam
expression. However, because we show correlation between
the miR-29 family and Adam expression in vitro, coupled
with the observation from others that forced expression of
miR29b is therapeutic in renal ﬁbrosis,13 this suggests that
the antiﬁbrotic effect observed could be mediated, at least in
part, through miR-29 family repression of Adams 12 and 19.
Further detailed experiments are warranted to address this.
In this study we show changes and regulation at the gene
expression level of Adams by canonical TGF-b signaling
(Figure 10). Adams could well be the conduits for TGF-b
cross-talks with other key signaling pathways such as angio-
tensin II, epidermal growth factor, and Notch, whose activity
precipitates ﬁbrosis in the tubulointerstitium. Adam-speciﬁc
intervention strategies, either pharmacologically or geneti-
cally, are needed to further elucidate their individual roles in
pathogenesis or resolution of renal ﬁbrosis, making them po-
tential candidates for targeted ﬁbrosis therapy in renal disease.
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